Total and High–Molecular Weight Adiponectin in Relation to Metabolic Variables at Baseline and in Response to an Exercise Treatment Program: Comparative Evaluation of Three Assays
Response to von Eynatten et al.
- Catherine J. Williams, MPH1,
- Aoife Brennan, MD1,
- Matthias Blüher, MD2 and
- Christos S. Mantzoros, MD1
- 1Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- 2Department of Internal Medicine III, University of Leipzig, Leipzig, Germany
- Address correspondence to Christos Mantzoros, MD, Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, 330 Brookline Ave., ST816, Boston, MA 02215. E-mail: cmantzor{at}bidmc.harvard.edu
The letter by von Eynatten et al. (1) provides unpublished data on the sensitivity of high–molecular weight (HMW) adiponectin versus total adiponectin in predicting metabolic outcomes. The authors focus on only one assay source (enzyme-linked immunosorbent assay; ALPCO Diagnostics, Salem, NH) and do not consider its predictive ability in comparison to other assays.
Whereas different sample sizes may have contributed to varying levels of statistical significance, the previously derived (2) effect estimates are largely comparable with those reported by von Eynatten et al. (1). More importantly, our data clearly show that both previously developed assays measuring total adiponectin (radioimmunoassay; …
